All In Biotech

Drug Trial Radar · NCT07467447

Effect of Retatrutide Versus Placebo in Participants Who Have Obesity or Are Overweight

A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

Feb 15, 2026

Primary completion

Mar 14, 2027

Study completion Feb 17, 2028

Sponsor

Lead sponsor
Hudson BiotechIndustry
Sponsor type
Industry
First posted
Mar 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 2, multicenter, randomized, double-blind, placebo-controlled study evaluating once-weekly subcutaneous retatrutide (LY3437943) at multiple maintenance dose levels versus placebo in adults with obesity or overweight with weight-related comorbidities (without type 2 diabetes), alongside standardized diet and physical activity counseling.

Conditions

  • Obesity

Interventions

  • Retatrutide (LY3437943)Drug

    subcutaneous injection, once weekly (dose per assigned arm).

  • PlaceboDrug

    subcutaneous injection, once weekly (schedule matched to an active arm).

  • Standardized diet and physical activity counseling throughout the study.Behavioral

    Standardized diet and physical activity counseling throughout the study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean percent change in body weight from randomization/baseline to Week 24.Time frame: 24 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University Shenzhen Hospital

    Shenzhen, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.